FDA Inspection 1264015 — Shandong Anxin Pharmaceutical Co., Ltd. (Laoling site)
The FDA completed an inspection of Shandong Anxin Pharmaceutical Co., Ltd. (Laoling site) on March 14, 2025 in Dezhou. The inspection was classified VAI (Voluntary Action Indicated — objectionable conditions were found but do not meet the threshold for regulatory action). Product area: Drugs.
Inspection Details
- Classification
- Voluntary Action Indicated (VAI) (VAI)
- End Date
- March 14, 2025
- Fiscal Year
- 2025
- Product Type
- Drugs
- Project Area
- Drug Quality Assurance
- Location
- Dezhou (China)